Re: Clover et al. Transformation of a non-secretory neuro-endocrine tumor to insulinoma after treatment with Sunitinib: a case report and review of the literature. J Oncol Pharm Pract 2018. DOI: 10.1177/1078155218791309: Sunitinib-associated hyperinsulinemic hypoglycemia in patients with neuroendocrine tumors: drug-effect or tumor transformation?

J Oncol Pharm Pract. 2019 Jun;25(4):1026. doi: 10.1177/1078155219829812. Epub 2019 Feb 13.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Female
  • Humans
  • Hypoglycemia / chemically induced
  • Hypoglycemia / diagnosis
  • Insulinoma / chemically induced*
  • Insulinoma / diagnosis
  • Neuroendocrine Tumors / chemically induced*
  • Neuroendocrine Tumors / diagnosis
  • Protein Kinase Inhibitors / adverse effects*
  • Sunitinib / adverse effects*

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Sunitinib